NUS Links:

Find a Collaborator

Home › Partnerships & Collaborations › Find a Collaborator › For Your Research Area

Cancer Stem Cells

A / Prof Alfredo FRANCO-OBREGON

Cancer Stem Cells

I approach tissue engineering, regeneration and development from a biophysical perspective, as an alternative to conventional pharmacological interventions. I am particularly interested in how mechanical and electromagnetic forces drive development and can be used to control disease. My areas of interest are skeletal muscle development, cancer and stem cell biology.

Prof Yoshiaki ITO

Cancer Stem Cells

Research focuses on the regulation of stem cells and cancer phenotype from two angles: IQGAP3 is a cytoskeletal protein tightly associated with proliferation and stem cell properties of cancer cells. RUNX3 is a transcription factor functions as a gatekeeper of gastric cancer, often silenced by promoter methylation.

A / Prof KOH Liang Piu

Cancer Stem Cells

Research focuses mainly on clinical Haematopoietic Stem Cell Transplantation in particular Nonmyeloablative Stem Cell Transplant, haploidentical donor transplant, Umbilical Cord Blood Transplantation in Haematological Malignancies. He also the leading primary investigators on clinical trials on Infectious Complications in Haematological / Haematopoietic Stem Cell Transplantation Recipients, studies on Graft vs. Host Disease prevention and treatment.

Dr LIM Gkeok Stzuan, Diana

Cancer Stem Cells

Dr Diana Lim is a senior consultant pathologist and director of the Diagnostic Molecular Oncology Centre (DMOC) in National University Hospital. Her subspecialty and research interest lies in gynaecologic and molecular pathology.

Dr ONG Sek Tong, Derrick

Cancer Stem Cells

Research focus is on identifying new glioblastoma dependency in the area of cancer epigenetics as we try to develop innovative and durable GBM treatment modalities. We are also interested to understand the mechanisms that regulate non-cancerous brain stem cell function, in order to discover new ways to retard/reverse brain aging.

Prof Toshio SUDA

Cancer Stem Cells

Research focus is based on the hypothesis that the bone marrow (BM) microenvironment known as the stem cells niche is essential for the maintenance of hematopoietic stem cells (HSC) quiescence in cell cycle and regulates the fate of HSCs. We aim for the regulation of stem cells by niche as niche therapy. We will dissect the niche as a functional unit of stem cell regulation and aim to expand stem cells using ex vivo artificial niches and improve the method for BM transplantation.

Prof Toshio SUDA

Cancer Stem Cells

Research focus is based on the hypothesis that the bone marrow (BM) microenvironment known as the stem cells niche is essential for the maintenance of hematopoietic stem cells (HSC) quiescence in cell cycle and regulates the fate of HSCs. We aim for the regulation of stem cells by niche as niche therapy. We will dissect the niche as a functional unit of stem cell regulation and aim to expand stem cells using ex vivo artificial niches and improve the method for BM transplantation.

A / Prof KOH Liang Piu

Cancer Stem Cells

Research focuses mainly on clinical Haematopoietic Stem Cell Transplantation in particular Nonmyeloablative Stem Cell Transplant, haploidentical donor transplant, Umbilical Cord Blood Transplantation in Haematological Malignancies. He also the leading primary investigators on clinical trials on Infectious Complications in Haematological / Haematopoietic Stem Cell Transplantation Recipients, studies on Graft vs. Host Disease prevention and treatment.

Prof Toshio SUDA

Cancer Stem Cells

Research focus is based on the hypothesis that the bone marrow (BM) microenvironment known as the stem cells niche is essential for the maintenance of hematopoietic stem cells (HSC) quiescence in cell cycle and regulates the fate of HSCs. We aim for the regulation of stem cells by niche as niche therapy. We will dissect the niche as a functional unit of stem cell regulation and aim to expand stem cells using ex vivo artificial niches and improve the method for BM transplantation.

Biomarkers / Imaging / Proteomics

A/Prof Glenn Kunnath BONNEY

Biomarkers

Dr CHEE Cheng Ean

Biomarkers

Research interest is in precision oncology in colorectal, pancreas and liver cancers. I develop and conduct clinical trials with novel therapeutics and work with collaborators within and outside Singapore on translational and biomarker research in these areas. In addition, I am interested in healthcare delivery and personalizing care for our cancer survivors.

A/Prof CHEN Zhi Xiong

Biomarkers

Neuroblastoma is the leading cause of cancer death in children. Our research is to develop improved approaches for treating neuroblastoma through drug repurposing and predicting outcome in paediatric tumours through blood sample monitoring.

Dr Jit Kong CHEONG

Biomarkers

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

A/Prof CHOW Kai-Hua, Edward

Imaging, Biomarkers

Research focus is on how to quickly and accurately identify effective cancer therapeutic options for individual cancer patients as well as specific sub-groups of cancer patients in both blood cancers and solid tumours.

A/Prof DENG Lih Wen

Biomarkers

Research focus is on understanding the cellular and molecular mechanism in cancer development and therapy resistance for the development of diagnostic markers and selective therapeutics against cancer resistance and metastasis.

Prof GOH Boon Cher

Biomarkers

Prof KHONG Pek-Lan

Imaging, Biomarkers

Prof LEE Soo Chin

Biomarkers

Research focuses on novel therapeutics and predictive biomarkers in breast cancer. Her team has identified a biomarker detectable in blood that predicts breast cancer recurrence, and that can be used to select patients for a novel targeted therapy.

Dr LIM Si Jing, Joline

Biomarkers

Dr Jun Siong LOW

Imaging/Proteomics

A/Prof NG Siok Bian

Biomarkers

Research focus is to identify and validate novel markers of prognostic and therapeutic importance in EBV-associated T- and NK-cell lymphomas and lymphoproliferative diseases, a group of aggressive tumours which are prevalent in Asia.

Dr NGOI Yan Li, Natalie

Biomarkers

Prof SO Bok Yan, Jimmy

Biomarkers

Research focus is to improve outcomes of patients with gastric or esophageal cancer through early detection, better understanding of their origins and novel treatment.

Dr Raghav SUNDAR

Biomarkers

Research focuses on identifying predictive biomarkers and potential therapeutic targets of systemic therapy in gastric cancer by incorporating contemporary technology such as spatial transcriptomics and machine-learning.

Dr TAI Yee Kit Alex

Biomarkers

Research focus is on exploring the therapeutic benefits of pulsed electromagnetic fields (PEMF) as an exercise-mimetic to enhance the vulnerability of tumor cells to chemotherapy

A/Prof TAN Shao Peng, David

Biomarkers

Research is focused on the development of biomarkers and novel therapeutic agents in gynaecological cancers; in understanding the mechanisms of treatment response and resistance in these cancers, with the aim of developing biomarkers to help stratify patients into optimal treatment strategies.

A/Prof TAY Mei Sian, Yvonne

Biomarkers

Research focuses on understanding the role of non-coding RNAs that play a part in cancer development and exploring their potential utility as diagnostic biomarkers and targeted therapeutics for precision medicine.

A/Prof TOO Heng-Phon

Biomarkers

Research focus is on developing diagnostic tools to detect early changes in the development of cancers using small amounts of blood. We are now focusing on gene engineering of cells for treatment of cancers and other diseases.

Dr Balamurugan A VELLAYAPPAN

Imaging

Research focus is on the use of advanced radiation technology, such as stereotactic ablative radiotherapy (SABR/SBRT) and stereotactic radiosurgery, in the context of neuro-oncology and oligo-metastatic disease. Also interested in the use of novel imaging techniques (such as functional imaging, MR and artificial intelligence) to improve the delivery of radiation

A/Prof WANG Lingzhi

Biomarkers

Research focus is on oncology drug development/evaluation pipeline that combines cell biology, pharmacological science, and pharmacokinetic analysis. Another important area of research is the discovery of non-invasive biomarkers for early detection of cancer in high-risk populations.

Dr WONG Li Ann, Andrea

Biomarkers

Certain cancer cells develop resistance to therapy by altering their metabolic dependencies. Our research centres on the development of oxidative phosphorylation inhibitors as a novel class of agents to overcome therapeutic resistance.

A/Prof YIP Wai Cheong, George

Biomarkers

Research interest is in understanding the biological roles of molecules called glycosaminoglycans and proteoglycans and to determine if these biomolecules can be used to predict patient outcomes and the development of new treatment.

Prof Yang ZHANG

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Dr ZHOU Jianbiao

Biomarkers

Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.

Prof Yang ZHANG

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Prof Yang ZHANG

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Cell Signaling

Prof Dario CAMPANA

Cell Signaling

Research focus is on the development of innovative technologies to treat cancer with immune cells, and their translation into first-in human clinical trials.

Dr CHEOK Chit Fang

Cell Signaling

Research focus is on understanding the cellular and molecular mechanism in cancer development and therapy resistance for the development of diagnostic markers and selective therapeutics against cancer resistance and metastasis.

Dr Jit Kong CHEONG

Cell Signaling

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

Dr Alan Prem KUMAR

Cell Signaling

Research focus is on uncovering new cues that drive the spread of cancer and develop target-based precision therapies to prevent metastasis in several types of female reproductive cancers.

Dr Jun Siong LOW

Cell Signaling

T and B cells are components of the immune system that are essential in fighting against infection-causing “foreign” pathogens, but are also involved in disease settings like cancer and autoimmunity where they can attack “self”. Our lab aims to understand the complex biology of T and B cells at the interplay of infection and cancer, by focusing on their phenotypic and functional profiles, antigen specificities and receptor repertoires. Our long-term goal is to develop rational and effective immune-based therapies to leverage on the immune system to fight cancer.

A/Prof Gautam SETHI

Cell Signaling

Research focus is to elucidate the mechanism(s) of activation of oncogenic transcription factors and identification of novel inhibitors of these proteins for cancer prevention as well as therapy.

Dr TAI Yee Kit

Cell Signaling

Research focus is on exploring the therapeutic benefits of pulsed electromagnetic fields (PEMF) as an exercise-mimetic to enhance the vulnerability of tumor cells to chemotherapy.

Dr ZHOU Jianbiao

Cell Signaling

Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.

Dr ZHOU Jianbiao

Cell Signaling

Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.

RNA Biology

A / Prof CHEN Leilei, Polly

RNA Biology

Research focus is on identifying how the harmful changes that occur in RNA molecules trigger a cell to develop into cancer which can eventually lead to the unsatisfactory treatment outcomes for patients with cancers. The long-term goal of Dr Chen’s team is to develop novel cancer therapies targeting these cancer-associated RNA changes.

Dr Jit Kong CHEONG

RNA Biology

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

A / Prof TAY Mei Sian, Yvonne

RNA Biology

Research focuses on understanding the role of non-coding RNAs that play a part in cancer development and exploring their potential utility as diagnostic biomarkers and targeted therapeutics for precision medicine.

A / Prof TOO Heng-Phon

RNA Biology

Research focus is on developing diagnostic tools to detect early changes in the development of cancers using small amounts of blood. We are now focusing on gene engineering of cells for treatment of cancers and other diseases.

Prof Yang ZHANG

RNA Biology

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Prof Yang ZHANG

RNA Biology

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Genomics / Epigenetics / Transcriptional regulation

A / Prof CHEN Ee Sin

Epigenetics

A / Prof CHEN Leilei, Polly

Epigenetics

Research focus is on identifying how the harmful changes that occur in RNA molecules trigger a cell to develop into cancer which can eventually lead to the unsatisfactory treatment outcomes for patients with cancers. The long-term goal of Dr Chen’s team is to develop novel cancer therapies targeting these cancer-associated RNA changes.

Dr Jit Kong CHEONG

Genomics

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

Prof CHNG Wee Joo

Genomics

Research focus is on blood cancers to understand how the disease develops and find better ways to treat them.

A / Prof DENG Lih Wen

Genomics

Research focus is on understanding the cellular and molecular mechanism in cancer development and therapy resistance for the development of diagnostic markers and selective therapeutics against cancer resistance and metastasis.

Dr Dennis KAPPEI

Transcriptional regulation

Research focus is on DNA-protein interactions and changes in chromatin composition by quantitative mass spectrometry. In particular, focus is on telomeres and their impact on genome stability as well as on related transcriptional regulation at (mutated) promoters or enhancers.

A/Prof LEE Kwan Min, Victor

Epigentics & Genomics

Research passion is in the field of bone and soft tissue tumours for both paediatric and adult patients. My general interest involves investigating the clinical, pathological characteristics and biology of these tumours. From there, I hope to identify and characterize the oncogenic mechanisms, test or develop biomarkers for diagnostic, prognostic and therapeutic applications.

A / Prof Norbert LEHMING

Genomics

Research focuses on using yeast as a tool to identify novel protein partners for human and yeast proteins that are relevant for important biological processes like the expression of genes and the repair of damaged DNA.

Dr LEONG Sai Mun

Genomics

Adapting the use of evolutionary game theory, sociobiology and mathematical modelling on top of conventional molecular and cellular oncology, my team and I aim to unveil the nature of social relationships amongst cancer cells and study how perturbation in these relationships may affect outcome of cancer treatment.

A / Prof LIM Gkeok Stzuan, Diana

Epigentics

Dr Diana Lim is a senior consultant pathologist and director of the Diagnostic Molecular Oncology Centre (DMOC) in National University Hospital. Her subspecialty and research interest lies in gynaecologic and molecular pathology.

Prof Shazib PERVAIZ

Genomics

Dr Jason PITT

Genomics

Research focus is on generating and applying computational methods to understand the causes and consequences of genomic instability in cancer. Additionally, we develop innovative genomic data democratization platforms to enhance scientific discovery as well as precision oncology.

A / Prof Takaomi SANDA

Transcriptional regulation

Research focuses on transcriptional regulation of cancers, by which master transcription factors affect cell fate and drive oncogenesis in a lineage- and stage-specific manner. He aims to translate these findings into clinical application to develop novel therapeutics.

Dr Sriram SRIDHARAN

Genomics

Research focus is to study how DNA replication is a source of genome instability. I aim to understand why and how the (epi)genome acts as an impediment to faithful DNA replication.

A / Prof TAM Wai Leong

Transcriptional regulation

Research focus is on harnessing functional genomics to understand dysregulation in cellular metabolism and cell state perturbations for revealing principles of cancer stemness, resistance and metastasis.

Dr TEE Wee Wei

Epigentics

Research interest is to study how cancer cells undergo epigenetic reprogramming to induce phenotypic plasticity, contributing to cancer cell metastasis that escape from therapeutic pressures and the emergence of drug-tolerant persistent state.

Prof Daniel TENEN

Transcriptional regulation, Epigenetics

Research focus is on gene regulation in normal cells and cancer, mainly in leukaemia, lung cancer, and liver cancer. Current interests are transcription factors, epigenetics, and weird long noncoding RNAs in these processes, as well as targeting the oncofoetal protein SALL4.

Prof Vinay TERGAONKAR

Epigenetics

Research focus is on inflammation, focussing on a master regulator known as NFkB transcription factor. It is involved in many major human diseases including cancer. We aim to identify targets and develop better targeted drugs to reduce side effects of currently existing anti-inflammatory drugs in the market.

Prof Ashok VENKITARAMAN

Genomics

Research focus is on deciphering the mechanisms underlying cancer susceptibility to intercept cancer evolution.

A/Prof YAP Suen Mei, Celestial

Genomics

The expertise and commitment of my research extend expansively across human diseases and human biology including cancer. In addition, we have special interests in the roles of the cytoskeleton in cancer. My research group has developed both in vitro techniques incorporating molecular and bioinformatics technology, as well as in vivo approaches to investigating human diseases such as cancers.

A / Prof YEOH Eng Juh, Allen

Genomics

Research focus is on improving Acute Lymphoblastic Leukaemia treatment in children and adults by better prediction of each patient’s risk of relapse using highly sensitive biomarkers like RNA-Seq and MRD measurements. A/Prof Yeoh works on immune cell therapy especially CAR-T cell therapy for leukaemia with Prof Dario Campana in NUSMed.

Dr YONG Wei Peng

Epigenetics

Prof Yang ZHANG

Genomics / Epigenetics / Transcriptional regulation

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Dr ZHOU Jianbiao

Genomics

Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.

NUS Centre for Cancer Research

© National University of Singapore. All Rights Reserved.